This offset contract for the production of medical products was the third one; Moscow has already entered into two offsets in pharmaceutics, both for a duration of 10 years. As part of the contracts, the city will localize the production of drugs for the treatment of cancer, cardiology, endocrine and immune diseases. Subsequently, drugs will be supplied to the capital for several years.
"The total volume of investments under two offsets in the pharmaceutical industry is 8.8 billion rub, and the volume of supply amounts to 32.4 billion rub. The contracts provide for import substitutions of more than half of all medicines needed: 27 out of 53 drugs that are to be produced at the new plants are not currently manufactured in Russia. At the moment, the projects are being implemented in the special economic zone in Zelenograd," said Vladimir Efimov, Deputy Mayor of the Department of Economic Policy and Landholding Affairs of Moscow Government.
The first offset contract was signed by Moscow in October 2017 with BIOCAD. According to its terms, the investor will establish a facility in the city to produce 22 modern cancer & immunology-related medicines and supply them over the course of 7 years. The contract's value is 14 billion rub, and the volume of investments in the facility is 3 billion rub.
R-Opra LLC became an investor under the terms of the second offset contract, which was signed in autumn of 2018. According to the contract, the production of 31 medicines will be localized to Moscow within 4 years, including the production of biological components necessary for 3 medicines. The supplier-investor will fulfill contractual obligations for 18.4 billion rub, and the investments under the second offset will amount to 5.8 billion rub for the creation of 12 production lines. The medicines to be produced under this contract include those used for the treatment and prevention of cancer, endocrine and cardiac-related diseases.